Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Subscriber?
Search

June 2011

What Future for Deeply-Discounted Lab Prices?

Commentary and Opinion by R. Lewis Dark /

IN THE LABORATORY TESTING INDUSTRY, there is probably no single issue that causes more rancor than the regular use of deeply-discounted pricing of laboratory tests by a certain cohort of laboratory companies. This fault line in our industry is quite distinct. Those managers and pathologists in lab organizations that refuse to use low cost pricing […]

To access this post, you must purchase The Dark Report.

What Future for Deeply-Discounted Lab Prices? Read More Ā»

Will Medi-Cal Price Case Bring More Enforcement?

Clinical Laboratory Trends /

CEO SUMMARY: It was on May 19 that the California Attorney General and Quest Diagnostics Incorporated signed an agreement to settle allegations that Quest Diagnostics overcharged Medi-Cal, the stateā€™s Medicaid program. It is expected that the California Attorney General will now move to resolve the whistleblower case against the remaining lab company defendants. Meanwhile, similar

To access this post, you must purchase The Dark Report.

Will Medi-Cal Price Case Bring More Enforcement? Read More Ā»

Quest Diagnostics Settles Medi-Cal Qui Tam Case

Clinical Laboratory Trends /

CEO SUMMARY: On May 19, the California Attorney General announced a $241 million agreement with Quest Diagnostics Incorporated that represents the largest settlement in the history of Californiaā€™s False Claims Act. At issue in this whistle- blower lawsuit were allegations that Quest Diagnostics, along with multiple other defendant lab companies, had overcharged Medi-Cal, which is

To access this post, you must purchase The Dark Report.

Quest Diagnostics Settles Medi-Cal Qui Tam Case Read More Ā»

Understanding the Deal With Medi-Cal and Quest

Laboratory Billing /

CEO SUMMARY: It is now possible to see the specific language in the ā€œSettlement Agreement and Releaseā€ document executed by the California State Attorney General and Quest Diagnostics Incorporated. For those clinical lab managersā€”and the attorneys who represent their laboratory companiesā€”there is mixed news and guidance about 51501(a) from this agreement. Thatā€™s because, while assenting

To access this post, you must purchase The Dark Report.

Understanding the Deal With Medi-Cal and Quest Read More Ā»

Quest Diagnostics to File Regular Reports with DHCS

Laboratory Billing /

CEO SUMMARY: Pathologists, clinical lab executives, and lawyers in California are going to find some surprises when they study the ā€œSettlement Agreement and Releaseā€ that was recently signed by the California Attorney General and Quest Diagnostics Incorporated. Quest Diagnostics has indeed agreed to pay $241 million to resolve the allegations in the whistleblower lawsuit. But

To access this post, you must purchase The Dark Report.

Quest Diagnostics to File Regular Reports with DHCS Read More Ā»

Medi-Cal Deal Raises Interesting Questions

Laboratory Billing /

CEO SUMMARY: From the perspective of the average citizen, it would appear that Quest Diagnostics scored two major ā€œwinsā€ over the California Attorney General in the negotiations as to how the whistleblower lawsuit was to be settled. Language in the settlement agreement would indicate that current lab sales and marketing practices involving deeply-discounted test prices

To access this post, you must purchase The Dark Report.

Medi-Cal Deal Raises Interesting Questions Read More Ā»

What Comes Next in Battle Over Discount Lab Prices?

Laboratory Billing /

CEO SUMMARY: Now that the settlement involving Quest Diagnostics Incorporated and the California Attorney General has been announced, attention turns to what comes next with the four remaining defendant lab companies in the whistle-blower lawsuit. There are several different scenarios and it may be that California regulators face tough challenges before they can succeed in

To access this post, you must purchase The Dark Report.

What Comes Next in Battle Over Discount Lab Prices? Read More Ā»

June 13, 2011 “Intelligence: Late Breaking Lab News”

Late Breaking Lab News /

In coming weeks, Agendia, probably best known for its genetic breast cancer test, hopes to complete an initial public offering (IPO). Agendia is a company based in Amsterdam, The Netherlands with offices in Irvine, California. Its stock symbol will be ā€œAGDXā€ and the shares will trade on the Euronext Amsterdam exchange. Plans are to raise

To access this post, you must purchase The Dark Report.

June 13, 2011 “Intelligence: Late Breaking Lab News” Read More Ā»

Facebook-f Twitter Linkedin-in

The Dark Report ā€¢ 21806 Briarcliff Dr ā€¢ Spicewood, TX 78669
Phone: 512-264-7103 ā€¢ Toll Free Number: 800-560-6363
Email: info@darkreport.com

Ā© 2024 The Dark Report. All rights reserved.

;